BioSpace News Archive

Deals

Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement

Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. today announced they have entered into a definitive merger agreement for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn.

April 19, 2022
·
8 min read
Drug Development

Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease

Neuraly today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).

April 19, 2022
·
5 min read
Business

Miroculus Appoints Mark Lewis as Executive Chairman

Miroculus, Inc. today announced the appointment of Mark Lewis as Executive Chairman.

April 19, 2022
·
2 min read
Business

Ncardia Launches Cellistic™, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today

Ncardia has launched a new business, Cellistic™, to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector.

April 19, 2022
·
5 min read
BioMidwest

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis

Navidea Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance for the patent application titled, “Compounds And Compositions For Treating Leishmaniasis And Methods Of Diagnosis And Treating Using Same” (U.S. Patent Application No. 15/729,633).

April 19, 2022
·
6 min read
Business

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.

April 19, 2022
·
22 min read
BioCapital

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in Japan Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination.

April 19, 2022
·
9 min read
Business

Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022

Amarin Corporation plc today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s first quarter 2022 financial results on Wednesday, May 4, 2022 at 8:00 a.m. ET.

April 19, 2022
·
1 min read
Drug Development

KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

KemPharm, Inc. today announced that the first subject has been dosed in a Phase 1 clinical trial designed to assess the relative cardiovascular safety of serdexmethylphenidate (SDX) compared to immediate-release and long-acting formulations of Ritalin® (racemic methylphenidate).

April 19, 2022
·
6 min read
Policy

Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica

Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. (“Janssen”), a subsidiary of Johnson & Johnson.

April 19, 2022
·
4 min read